급성 허혈성 뇌졸중 시장 - 세계 및 지역별 분석 : 치료제별, 지역별 - 분석과 예측(2025-2035년)

Global Acute Ischemic Stroke Market, Analysis and Forecast: 2025-2035

An acute ischemic stroke occurs when a blood clot obstructs a blood vessel supplying blood to the brain, leading to a sudden loss of neurological function. This blockage deprives brain tissue of essential oxygen and nutrients, causing cell death and potential long-term disability.

One of the significant drivers of the global acute ischemic stroke market is the rising incidence of lifestyle disorders. The rising ages and lifestyle-related diseases such as hypertension, diabetes, and obesity which leads to increases the risk of ischemic stroke. This results in increasing demand of drug or therapies during the treatment.

Despite the positive growth trajectory, several challenges continue to impact the global acute ischemic stroke market. One of the primary challenges is limited access to advanced care in low-resource settings. However, the advanced treatments like tPA and thrombectomy have improved outcomes, many regions lack the necessary infrastructure to deliver these therapies. This results in underdiagnosis and delayed treatments, significantly increasing stroke-related disability and mortality.

The global acute ischemic stroke market is also facing high cost of treatment. However, the cost of cutting-edge treatments like mechanical thrombectomy, tPA, and post-stroke rehabilitation can be prohibitive for patients and healthcare systems, particularly in developing regions.

The companies play pivotal roles in advancing the treatment landscape for ischemic stroke through the development of targeted therapies. Their ongoing research and collaborations are essential in improving patient outcomes and expanding therapeutic options in this market.

The competitive landscape of the global acute ischemic stroke market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific. As consumer preferences shift towards more discreet, comfortable, and affordable therapies, the acute ischemic stroke market will continue to evolve, fostering new opportunities for both established and emerging companies.

Market Segmentation:

Segmentation 1: by Therapeutics

• Thrombolytic Therapies
• Antiplatelet Therapies
• Antihypertensive Therapies
• Anticoagulants

Segmentation 2: by Region

• North America
• Europe
• Asia-Pacific

In conclusion, the global acute ischemic stroke market is on track for continued growth, driven by the growing healthcare investments and research. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for acute ischemic stroke market rises the therapies, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Global Acute Ischemic Stroke Market: Industry Outlook

• 1.1 Overview
• 1.2 Regulatory Landscape of Acute Ischemic Stroke
• 1.3 Acute Ischemic Stroke Market, Epidemiology Analysis
• 1.4 Acute Ischemic Stroke Market, Patent Landscape
  • 1.4.1 By Country
  • 1.4.2 By Year
• 1.5 Acute Ischemic Stroke Market, Clinical Trials Landscape
• 1.6 Key Trends
• 1.7 Market Dynamics
  • 1.7.1 Impact Analysis
  • 1.7.2 Market Drivers
  • 1.7.3 Market Restraints
  • 1.7.3 Market Opportunities

2. Global Acute Ischemic Stroke Market, By Therapeutics, $Million, 2023-2035

• 2.1 Thrombolytic Therapies
• 2.2 Antiplatelet Therapies
• 2.3 Antihypertensive Therapies
• 2.4 Anticoagulants

3. Global Acute Ischemic Stroke Market, by Region, $Million, 2023-2035

• 3.1 North America
  • 3.1.1 Key Findings in North America
  • 3.1.2 Business Drivers
  • 3.1.3 Business Challenges
  • 3.1.4 Market Sizing and Forecast
    • 3.1.4.1 North America Acute Ischemic Stroke Market, By Country
      • 3.1.4.1.1 U.S.
• 3.2 Europe
  • 3.2.1 Key Findings in Europe
  • 3.2.2 Business Drivers
  • 3.2.3 Business Challenges
  • 3.2.4 Market Sizing and Forecast
    • 3.2.4.1 Europe Acute Ischemic Stroke Market, By Country
      • 3.2.4.1.1 Germany
      • 3.2.4.1.2 U.K.
      • 3.2.4.1.3 France
      • 3.2.4.1.4 Italy
      • 3.2.4.1.5 Spain
• 3.3 Asia-Pacific
  • 3.3.1 Key Findings in Asia-Pacific
  • 3.3.2 Business Drivers
  • 3.3.3 Business Challenges
  • 3.3.4 Market Sizing and Forecast
    • 3.3.4.1 Asia-Pacific Acute Ischemic Stroke Market, By Country
      • 3.3.4.1.1 Japan

4. Competitive Landscape and Company Profiles

• 4.1 Competitive Landscape
  • 4.1.1 New Offerings
  • 4.1.2 Mergers and Acquisitions
  • 4.1.3 Partnerships, Alliances, and Business Expansion
  • 4.1.4 Funding Activities
  • 4.1.5 Regulatory Approvals
• 4.2 Company Profile
  • 4.2.1 Acticor Biotech
    • 4.2.1.1 Overview
    • 4.2.1.2 Product Portfolio
    • 4.2.1.3 Target Customers
    • 4.2.1.4 Key Professionals
    • 4.2.1.5 Analyst View
  • 4.2.2 Bristol-Myers Squibb
    • 4.2.2.1 Overview
    • 4.2.2.2 Product Portfolio
    • 4.2.2.3 Target Customers
    • 4.2.2.4 Key Professionals
    • 4.2.2.5 Analyst View
  • 4.2.3 Genentech, Inc
    • 4.2.3.1 Overview
    • 4.2.3.2 Product Portfolio
    • 4.2.3.3 Target Customers
    • 4.2.3.4 Key Professionals
    • 4.2.3.5 Analyst View
  • 4.2.4 Athersys|Healios K.K.
    • 4.2.3.1 Overview
    • 4.2.3.2 Product Portfolio
    • 4.2.3.3 Target Customers
    • 4.2.3.4 Key Professionals
    • 4.2.3.5 Analyst View
  • 4.2.5 Biogen Inc
    • 4.2.5.1 Overview
    • 4.2.5.2 Product Portfolio
    • 4.2.5.3 Target Customers
    • 4.2.5.4 Key Professionals
    • 4.2.5.5 Analyst View
  • 4.2.6 AbbVie
    • 4.2.6.1 Overview
    • 4.2.6.2 Product Portfolio
    • 4.2.6.3 Target Customers
    • 4.2.6.4 Key Professionals
    • 4.2.6.5 Analyst View
  • 4.2.7 Revalesio Corporation
    • 4.2.7.1 Overview
    • 4.2.7.2 Product Portfolio
    • 4.2.7.3 Target Customers
    • 4.2.7.4 Key Professionals
    • 4.2.7.5 Analyst View
  • 4.2.8 NoNO Inc.
    • 4.2.8.1 Overview
    • 4.2.8.2 Product Portfolio
    • 4.2.8.3 Target Customers
    • 4.2.8.4 Key Professionals
    • 4.2.8.5 Analyst View
  • 4.2.9 Bayer
    • 4.2.9.1 Overview
    • 4.2.9.2 Product Portfolio
    • 4.2.9.3 Target Customers
    • 4.2.9.4 Key Professionals
    • 4.2.9.5 Analyst View
  • 4.2.10 TrueBinding, Inc
    • 4.2.10.1 Overview
    • 4.2.10.2 Product Portfolio
    • 4.2.10.3 Target Customers
    • 4.2.10.4 Key Professionals
    • 4.2.10.5 Analyst View
  • 4.2.11 Lumosa Therapeutics
    • 4.2.11.1 Overview
    • 4.2.11.2 Product Portfolio
    • 4.2.11.3 Target Customers
    • 4.2.11.4 Key Professionals
    • 4.2.11.5 Analyst View
  • 4.1.12 Janssen Pharmaceutical
    • 4.2.12.1 Overview
    • 4.2.12.2 Product Portfolio
    • 4.2.12.3 Target Customers
    • 4.2.12.4 Key Professionals
    • 4.2.12.5 Analyst View
  • 4.2.13 Silver Creek Pharmaceuticals
    • 4.2.13.1 Overview
    • 4.2.13.2 Product Portfolio
    • 4.2.13.3 Target Customers
    • 4.2.13.4 Key Professionals
    • 4.2.13.5 Analyst View

5. Research Methodology